Skip to main content

CORRECTION article

Front. Oncol., 25 August 2022
Sec. Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers
Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.991401
This article is part of the Research Topic Hepatocellular Carcinoma: from Basic Research to Clinical Trials View all 24 articles

Corrigendum: Blockade of uttroside B-induced autophagic pro-survival signals augments its chemotherapeutic efficacy against hepatocellular carcinoma

This article is a correction to:

  1. Blockade of Uttroside B-Induced Autophagic Pro-Survival Signals Augments Its Chemotherapeutic Efficacy Against Hepatocellular Carcinoma

    1. Read original article
Lekshmi R. Nath&#x;&#x;Lekshmi R. Nath1†‡Mundanattu Swetha&#x;Mundanattu Swetha1‡Vinod Vijayakurup&#x;&#x;Vinod Vijayakurup1†‡Arun Kumar Thangarasu,&#x;Arun Kumar Thangarasu2,3‡Nair Hariprasad HarithaNair Hariprasad Haritha1Anwar ShabnaAnwar Shabna1Sreekumar U. Aiswarya,Sreekumar U. Aiswarya1,4Tennyson P. RayginiaTennyson P. Rayginia1C. K. KeerthanaC. K. Keerthana1Kalishwaralal KalimuthuKalishwaralal Kalimuthu1Sankar SundaramSankar Sundaram5Ravi Shankar Lankalapalli,Ravi Shankar Lankalapalli2,3Sreekumar PillaiSreekumar Pillai6Rheal TownerRheal Towner7Noah IsakovNoah Isakov8Ruby John Anto*Ruby John Anto1*
  • 1Division of Cancer Research, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, India
  • 2Chemical Sciences and Technology Division, Council for Scientific and Industrial Research (CSIR)-National Institute for Interdisciplinary Science and Technology, Thiruvananthapuram, India
  • 3Academy of Scientific & Innovative Research (AcSIR), Ghaziabad, India
  • 4Department of Biotechnology, University of Calicut, Malappuram, India
  • 5Department of Pathology, Government Medical College, Kottayam, India
  • 6Department of Surgical Oncology, Jubilee Mission Medical College and Research Institute, Thrissur, India
  • 7Department of Pathology and Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma, United States
  • 8The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer Sheva, Israel

A corrigendum on
Blockade of uttroside B-induced autophagic pro-survival signals augments Its chemotherapeutic efficacy against hepatocellular carcinoma

by Nath LR, Swetha M, Vijayakurup V, Thangarasu AK, Haritha HN, Shabna A, Aiswarya SU, Rayginia TP, Keerthana CK, Kalimuthu K, Sundaram S, Lankalapalli RS, Pillai S, Towner R, Isakov N and Anto RJ (2022). . 12:812598. doi: 10.3389/fonc.2022.812598

Incorrect Supplementary Material

In the published article, there was an error in Supplementary Figure 1B. A Duplicate image was given in Wound healing assay images of 0h Cqn (10µM) and Utt-B (250nM). The correct material statement appears below. There is no change in the wordings of the manuscript.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.991401/full#supplementary-material

Keywords: autophagy, chloroquine, apoptosis, uttroside B, hepatocellular carcinoma, chemoprevention

Citation: Nath LR, Swetha M, Vijayakurup V, Thangarasu AK, Haritha NH, Shabna A, Aiswarya SU, Rayginia TP, Keerthana CK, Kalimuthu K, Sundaram S, Lankalapalli RS, Pillai S, Towner R, Isakov N and Anto RJ (2022) Corrigendum: Blockade of uttroside B-induced autophagic pro-survival signals augments its chemotherapeutic efficacy against hepatocellular carcinoma. Front. Oncol. 12:991401. doi: 10.3389/fonc.2022.991401

Received: 11 July 2022; Accepted: 09 August 2022;
Published: 25 August 2022.

Edited and Reviewed by:

Zhou Jiang, University of Texas MD Anderson Cancer Center, United States

Copyright © 2022 Nath, Swetha, Vijayakurup, Thangarasu, Haritha, Shabna, Aiswarya, Rayginia, Keerthana, Kalimuthu, Sundaram, Lankalapalli, Pillai, Towner, Isakov and Anto. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Ruby John Anto, cmphbnRvQHJnY2IucmVzLmlu

†Present address: Lekshmi R. Nath, Department of Pharmacognosy, Amrita School of Pharmacy, Amrita
Vishwa Vidyapeetham, AIMS Health Science Campus, Kochi, India
Vinod Vijayakurup, Department of Anatomy and Cell Biology, Cancer and Genetics Research Complex, University of Florida, Gainesville, FL, United States

‡These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.